Lung Neoplasm Malignant Clinical Trial
— BUDDYOfficial title:
Evaluation of Blood Tumor Mutation Burden (TMB) for Improved Efficacy of Atezolizumab in 2nd Line Non-small Cell Lung Cancer (NSCLC) [BUDDY]
Verified date | February 2023 |
Source | Chonnam National University Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is single arm, prospective, multi-center, cohort study to evaluate blood TMB for improved efficacy of atezolizumab in locally advanced or metastatic NSCLC at the study enrollment who failed one or more prior lines of chemotherapy including at least 1 platinum-based.
Status | Completed |
Enrollment | 100 |
Est. completion date | June 30, 2022 |
Est. primary completion date | December 31, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Signed Informed Consent Form 2. Ability to comply with protocol 3. Aged = 18 years 4. Histologically or cytologically confirmed NSCLC that is locally advanced or metastatic (i.e., Stage IIIB not eligible for definitive chemoradiotherapy, Stage IV, or recurrent) NSCLC at the study enrollment 5. Disease progression during or following treatment with a prior platinum-containing regimen for NSCLC - Patients may have received one or more additional cytotoxic chemotherapy regimen. - Patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations should have disease progression on approved therapy for these aberrations prior to receiving atezolizumab. 6. Measurable disease, as defined by RECIST v1.1 Measurable disease is defined by the presence of at least one measurable lesion by RECIST v1.1 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2 8. Life expectancy = 12 weeks 9. Adequate hematologic and end organ function: - Absolute neutrophil count (ANC) = 1.0 x 109/L - White blood cell (WBC) counts > 2.5 x 109/L - Hemoglobin = 8.0 g/dL - Total bilirubin = 2.5 X upper limit of normal (ULN) Patients with known Gilbert's disease who have serum bilirubin level = 3 x ULN may be enrolled. - Aspartate aminotransferase (AST), alanine transaminase (ALT), and alkaline phosphatase = 2.5 × ULN, with the following exceptions: Patients with documented liver metastases: AST and ALT = 5 × ULN Patients with documented liver or bone metastases: alkaline phosphatase = 5 × ULN Exclusion Criteria: 1. Active or untreated central nervous system (CNS) metastases Patients with a history of treated CNS metastases that are asymptomatic are eligible 2. Malignancies other than NSCLC within 5 years prior to study enrollment, with the exception of those with a negligible risk of metastasis or death and treated with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated with curative intent, or ductal carcinoma in situ treated surgically with curative intent) 3. Pregnant and lactating women • Women of childbearing potential should use effective contraception during treatment with atezolizumab and for at least 5 months following the last dose. 4. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within 3 months prior to study enrollment 5. Patients with autoimmune disorder or a history of chronic or recurrent autoimmune disorder - Patients with a history of autoimmune-mediated hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study. - Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible for this study. 6. Uncontrolled idiopathic pulmonary fibrosis or drug-induced pneumonitis 7. Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to study enrollment • Treatment with inhaled corticosteroid or megesterol acetate is permitted. 8. Patient with a known hypersensitivity to atezolizumab or any of the excipients |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Chonnam National University Hwasun Hospital | Hwasun | Jeollanam-do |
Lead Sponsor | Collaborator |
---|---|
Chonnam National University Hospital | Roche Pharma AG |
Korea, Republic of,
Gandara DR, Paul SM, Kowanetz M, Schleifman E, Zou W, Li Y, Rittmeyer A, Fehrenbacher L, Otto G, Malboeuf C, Lieber DS, Lipson D, Silterra J, Amler L, Riehl T, Cummings CA, Hegde PS, Sandler A, Ballinger M, Fabrizio D, Mok T, Shames DS. Blood-based tumor — View Citation
Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JI, Kim K, Liu XQ, Sher X, Jung H, Lee M, Lee S, Park SH, Park JO, Park YS, Lim HY, Lee H, Choi M, Talasaz A, Kang PS, Cheng J, Loboda A, Lee J, Kang WK. Comprehensive molecular characterization of clinical r — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective response rate (ORR) | ORR between blood TMB-High vs. Low group | At the end of cycle 3 (each cycle is 21 days) | |
Secondary | Progression-free survival (PFS) | PFS in Intention-to-treat (ITT) population and subgroups according to blood TMB and programmed cell death-1 (PDL1) status | At the end of cycle 3 (each cycle is 21 days) | |
Secondary | Safety profile | Incidence of Treatment-related Adverse Events as assessed by CTCAE version 4 | Through study completion, an average of 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05890872 -
Aliya™ Pulsed Electric Fields (PEF) for Advanced Cancer
|
N/A | |
Recruiting |
NCT05974475 -
MONDRIAN: Multi-omics Integrative Modelling for Stereotactic Body Radiotherapy in Early-stage Non-small Cell Lung Cancer
|
||
Recruiting |
NCT06079970 -
Confocal Laser Endomicroscopy VERification
|
N/A | |
Recruiting |
NCT04973293 -
Preoperative Sintilimab Combined With Bevacizumab and Chemotherapy for Resectable Non-Small Cell Lung Cancer
|
N/A | |
Recruiting |
NCT04778826 -
Immune Response Following Lobectomy Along With or Without Bilateral Transcervical Mediastinal Lymphadenectomy
|
N/A | |
Suspended |
NCT04036721 -
Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis
|
Phase 4 | |
Completed |
NCT03352245 -
Feasibility of an Activity Regimen in Patients With Advanced Stage Lung Cancer
|
N/A | |
Completed |
NCT03834116 -
Resistance Inspiratory Muscle Training for Patients With Thoracic Malignancies
|
N/A | |
Completed |
NCT03824977 -
Prognostic Value of the 6-minute Stepper Test in Non-small Cell Lung Cancer Surgery
|
||
Terminated |
NCT02985203 -
Oral Navelbine and Cisplatin Followed by Metronomic Oral Navelbine in Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT06440616 -
Benefit of Spectral Information in Patients Suspected for Lung Cancer
|
N/A | |
Active, not recruiting |
NCT05241873 -
(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations
|
Phase 1/Phase 2 | |
Completed |
NCT05404022 -
Feasibility Trial of a Personalised Nutrition and Activity Programme for People With Lung Cancer Over 65 Years
|
N/A | |
Not yet recruiting |
NCT05414188 -
Beneficial Effect of Pulmonary Rehabilitation in Lung Cancer Patients Receiving Radiation Therapy
|
N/A | |
Recruiting |
NCT03525782 -
Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC
|
Phase 1/Phase 2 | |
Terminated |
NCT05013554 -
Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors
|
Phase 1 |